A Phase 2, Uncontrolled, Two-stage, Dose-escalations Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical activity of OMS721 in Adults with Thrombotic Microangiopathies
Administered By
Awarded By
Contributors
- Ortel, Thomas Lee Principal Investigator
Start/End
- August 1, 2014 - July 31, 2022